Bioventus delivered Q4 revenue growth with strong organic expansion and improved profitability. Net income turned positive year over year and adjusted EBITDA increased significantly, supported by strong demand in Pain Treatments and disciplined cost management.
Revenue reached $157.9M, up 2.8% reported and 10.0% organic growth.
Net income attributable to Bioventus improved to $14.8M from a prior-year net loss.
Adjusted EBITDA increased 30% year-over-year to $36.7M driven by higher margins and operating leverage.
Strong demand in Pain Treatments drove double-digit growth while Restorative Therapies declined due to the Advanced Rehabilitation divestiture.
Bioventus expects continued growth and profitability expansion in 2026 supported by portfolio demand and improved cash generation.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance